Hims & Hers Expands Weight Loss Offering, Adds Lilly's Zepbound to Platform

Dow Jones2025-04-02

By Sabela Ojea

Hims & Hers is expanding its weight-loss offering on its telehealth platform with the addition of Eli Lilly's Zepbound prescription and generic liraglutide.

The stock was up 7% to $31.62 in afternoon trading. Shares have risen around 31% year to date.

The telehealth-consultation platform on Tuesday said its aim is to bring customers more treatment options that best suit their needs.

"We've now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform," the company said.

Hims & Hers' platform already offers weight-loss brands including Novo Nordisk's Ozempic and Wegovy.

Hims & Hers plans to continue expanding its weight loss offering to deliver a more personalized experience to its customer base, the company added.

"All of this is part of our long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond," Hims & Hers said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

April 01, 2025 15:02 ET (19:02 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2524123021?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 03:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524123021","market":"sg","top_or_hot":-1,"title":"Hims & Hers Expands Weight Loss Offering, Adds Lilly's Zepbound to Platform","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Hims &amp; Hers is expanding its weight-loss offering on its telehealth platform with the addition of Eli Lilly's Zepbound prescription and generic liraglutide. \n</p>\n<p>\n  The stock was up 7% to $31.62 in afternoon trading. Shares have risen around 31% year to date. \n</p>\n<p>\n  The telehealth-consultation platform on Tuesday said its aim is to bring customers more treatment options that best suit their needs. \n</p>\n<p>\n  \"We've now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,\" the company said. \n</p>\n<p>\n  Hims &amp; Hers' platform already offers weight-loss brands including Novo Nordisk's Ozempic and Wegovy. \n</p>\n<p>\n  Hims &amp; Hers plans to continue expanding its weight loss offering to deliver a more personalized experience to its customer base, the company added. \n</p>\n<p>\n  \"All of this is part of our long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond,\" Hims &amp; Hers said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 01, 2025 15:02 ET (19:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Expands Weight Loss Offering, Adds Lilly's Zepbound to Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Expands Weight Loss Offering, Adds Lilly's Zepbound to Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-02 03:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Hims &amp; Hers is expanding its weight-loss offering on its telehealth platform with the addition of Eli Lilly's Zepbound prescription and generic liraglutide. \n</p>\n<p>\n  The stock was up 7% to $31.62 in afternoon trading. Shares have risen around 31% year to date. \n</p>\n<p>\n  The telehealth-consultation platform on Tuesday said its aim is to bring customers more treatment options that best suit their needs. \n</p>\n<p>\n  \"We've now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,\" the company said. \n</p>\n<p>\n  Hims &amp; Hers' platform already offers weight-loss brands including Novo Nordisk's Ozempic and Wegovy. \n</p>\n<p>\n  Hims &amp; Hers plans to continue expanding its weight loss offering to deliver a more personalized experience to its customer base, the company added. \n</p>\n<p>\n  \"All of this is part of our long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond,\" Hims &amp; Hers said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 01, 2025 15:02 ET (19:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2524123021","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524123021","pubTimestamp":1743534120,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hims & Hers is expanding its weight-loss offering on its telehealth platform with the addition of Eli Lilly's Zepbound prescription and generic liraglutide.The stock was up 7% to $31.62 in afternoon trading. Shares have risen around 31% year to date.The telehealth-consultation platform on Tuesday said its aim is to bring customers more treatment options that best suit their needs.\"We've now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,\" the company said.Hims & Hers' platform already offers weight-loss brands including Novo Nordisk's Ozempic and Wegovy.Hims & Hers plans to continue expanding its weight loss offering to deliver a more personalized experience to its customer base, the company added.\"All of this is part of our long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond,\" Hims & Hers said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","HIMS":"Hims & Hers Health Inc."},"translate_title":"Hims&Hers扩大减肥产品，将礼来公司的Zepbound添加到平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":0.9},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Hims & Hers is expanding its weight-loss offering on its telehealth platform with the addition of Eli Lilly's Zepbound prescription and generic liraglutide. \n\n\n  The stock was up 7% to $31.62 in afternoon trading. Shares have risen around 31% year to date. \n\n\n  The telehealth-consultation platform on Tuesday said its aim is to bring customers more treatment options that best suit their needs. \n\n\n  \"We've now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,\" the company said. \n\n\n  Hims & Hers' platform already offers weight-loss brands including Novo Nordisk's Ozempic and Wegovy. \n\n\n  Hims & Hers plans to continue expanding its weight loss offering to deliver a more personalized experience to its customer base, the company added. \n\n\n  \"All of this is part of our long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond,\" Hims & Hers said. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 15:02 ET (19:02 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2524123021","isCrawlerRequest":true}